Compare SWBI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | ADCT |
|---|---|---|
| Founded | 1852 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.2M | 484.4M |
| IPO Year | 2000 | 2019 |
| Metric | SWBI | ADCT |
|---|---|---|
| Price | $14.63 | $3.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $14.00 | $7.75 |
| AVG Volume (30 Days) | 646.9K | ★ 750.6K |
| Earning Date | 03-05-2026 | 03-10-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $81,357,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | $68.29 |
| P/E Ratio | $297.00 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $7.73 | $1.05 |
| 52 Week High | $15.40 | $4.98 |
| Indicator | SWBI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 69.10 | 39.10 |
| Support Level | $13.65 | $3.25 |
| Resistance Level | N/A | $3.87 |
| Average True Range (ATR) | 0.42 | 0.27 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 56.57 | 4.36 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).